348 related articles for article (PubMed ID: 28236297)
21. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
[TBL] [Abstract][Full Text] [Related]
22. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
Garcia C; Lyon L; Conell C; Littell RD; Powell CB
Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
[TBL] [Abstract][Full Text] [Related]
23. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
24. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
[TBL] [Abstract][Full Text] [Related]
25. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
[TBL] [Abstract][Full Text] [Related]
26. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH
Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922
[TBL] [Abstract][Full Text] [Related]
27. Short-term impact of surgically induced menopause on cognitive function and wellbeing in women at high risk for ovarian cancer following risk-reducing bilateral salpingo-oophorectomy.
Chang H; Kamara D; Bresee C; Lester J; Cass I
Menopause; 2020 Dec; 28(4):354-359. PubMed ID: 33350669
[TBL] [Abstract][Full Text] [Related]
28. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
[TBL] [Abstract][Full Text] [Related]
29. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Kotsopoulos J; Gronwald J; Karlan BY; Huzarski T; Tung N; Moller P; Armel S; Lynch HT; Senter L; Eisen A; Singer CF; Foulkes WD; Jacobson MR; Sun P; Lubinski J; Narod SA;
JAMA Oncol; 2018 Aug; 4(8):1059-1065. PubMed ID: 29710224
[TBL] [Abstract][Full Text] [Related]
30. Impact of risk-reducing salpingo-oophorectomy in premenopausal women.
Vermeulen RFM; Beurden MV; Korse CM; Kenter GG
Climacteric; 2017 Jun; 20(3):212-221. PubMed ID: 28509627
[TBL] [Abstract][Full Text] [Related]
31. Urinary incontinence more than 15 years after premenopausal risk-reducing salpingo-oophorectomy: a multicentre cross-sectional study.
Terra L; Heemskerk-Gerritsen BAM; Beekman MJ; Engelhardt E; Mourits MJE; van Doorn HC; de Hullu JA; Mom CH; Slangen BFM; Gaarenstroom KN; van Beurden M; Roeters Van Lennep JE; van Dorst EBL; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Steensma AB; van Leeuwen FE
BJOG; 2024 Jan; 131(1):99-108. PubMed ID: 37394722
[TBL] [Abstract][Full Text] [Related]
32. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
[TBL] [Abstract][Full Text] [Related]
33. Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?
Loizzi V; Dellino M; Cerbone M; Arezzo F; Chiariello G; Lepera A; Cazzato G; Cascardi E; Damiani GR; Cicinelli E; Cormio G
Hormones (Athens); 2023 Mar; 22(1):19-23. PubMed ID: 36637775
[TBL] [Abstract][Full Text] [Related]
34. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
Manchanda R; Legood R; Pearce L; Menon U
Gynecol Oncol; 2015 Dec; 139(3):487-94. PubMed ID: 26436478
[TBL] [Abstract][Full Text] [Related]
35. Sexuality and quality of life in women with a prior diagnosis of breast cancer after risk-reducing salpingo-oophorectomy.
Tucker PE; Saunders C; Bulsara MK; Tan JJ; Salfinger SG; Green H; Cohen PA
Breast; 2016 Dec; 30():26-31. PubMed ID: 27592287
[TBL] [Abstract][Full Text] [Related]
36. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
[TBL] [Abstract][Full Text] [Related]
37. Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea.
Kim HY; Park J; Moon SJ; Jeong S; Hong JH; Lee JK; Cho GJ; Cho HW
Cancer Res Treat; 2024 Jan; 56(1):143-148. PubMed ID: 37591780
[TBL] [Abstract][Full Text] [Related]
38. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.
van Driel CM; de Bock GH; Arts HJ; Sie AS; Hollema H; Oosterwijk JC; Mourits MJ
Maturitas; 2015 Mar; 80(3):318-22. PubMed ID: 25600260
[TBL] [Abstract][Full Text] [Related]
39. Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
Ricciardi E; Tomao F; Aletti G; Bazzurini L; Bocciolone L; Boveri S; Landoni F; Lapresa MT; Maruccio M; Parma G; Peccatori F; Petrella MC; Zanagnolo V; Colombo N; Maggioni A
Anticancer Res; 2017 Sep; 37(9):5241-5248. PubMed ID: 28870960
[TBL] [Abstract][Full Text] [Related]
40. Sexual function, menopausal symptoms, depression and cancer worry in women with BRCA mutations.
Powell CB; Alabaster A; Le A; Stoller N; Armstrong MA; Raine-Bennett T
Psychooncology; 2020 Feb; 29(2):331-338. PubMed ID: 31654466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
